Dive into some
exciting news

SeaStar Medical recognizes that key inflammatory messengers can be transformed. See how we're transforming medicine.

Disruptive thinking from a solutions-oriented organization

SeaStar Medical is a privately held, clinical-stage medical therapeutics company headquartered in Denver, Colorado. Our revolutionary Selective Cytopheretic Device (SCD) is in the final stages of clinical testing with an anticipated launch date in the second half of 2021.

For any media inquiries, please contact psconsulting@seastarmed.com.

Latest News

Ohio State Uses Experimental Therapy to Combat Excess Inflammation in COVID-19 Patients

COLUMBUS, Ohio – Researchers at The Ohio State University Wexner Medical Center are the first in Ohio to test a therapy that reduces the uncontrolled inflammation in COVID-19 patients that has been linked to severe respiratory distress, heart inflammation, multi-organ failure and death. Using the SeaStar Medical CLR 2.0 filter, doctors are filtering patient blood to remove immune system proteins called cytokines. The cytokines set off severe inflammation causing the lungs to fill with fluid making it difficult to breathe. Patients can develop acute respiratory distress syndrome, multi-organ failure and myocarditis. “By limiting the cytokines in the blood, we can prevent

Read more >

SeaStar Medical to Initiate a Pilot Study of Selective Cytopheretic Device in COVID-19 patients with Acute Respiratory Distress Syndrome and Acute Kidney Injury

Trial will test clinical activity, safety and efficacy of novel immunomodulating medical device to reverse and repair organ injury. DENVER, April 28, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced it has received approval of their Investigational Device Exemption (IDE) supplement from the U.S. Food and Drug Administration (FDA) to initiate a feasibility, compassionate use study. The immunomodulating medical device, the Selective Cytopheretic Device (SCD), will focus on positive COVID-19 patients with acute respiratory distress syndrome (ARDS) or Acute Kidney Injury (AKI). The IDE supplement approval recognizes there

Read more >

Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

Collaboration enables the development of Aethlon’s Hemopurifier in tandem with SeaStar’s cartridges for multiple clinical targets. SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients. Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar’s platform of cartridges

Read more >

The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.